A Multimodal AI Model May Improve Recurrence Risk Stratification in Early Breast Cancer
New model provided better prognostic information for recurrence in HR-positive, HER2-negative breast cancer than the Oncotype DX 21-gene recurrence...
New model provided better prognostic information for recurrence in HR-positive, HER2-negative breast cancer than the Oncotype DX 21-gene recurrence...
SAN ANTONIO – Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they...
Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to...
SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant...
More than 30 new drugs have been approved for pediatric cancer in the past 10 years, but progress has...
AI-powered, multilingual cancer research pipeline will accelerate the pace of global data curation and expand access to real-world clinical...
SAN ANTONIO – The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor...
PHILADELPHIA – The American Association for Cancer Research (AACR) today congratulated Richard Pazdur, MD, on his appointment as Director...
PHILADELPHIA – The American Association for Cancer Research (AACR) today released a policy statement in support of a rule proposed...
PHILADELPHIA – Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL)...